Suppr超能文献

与开放性细胞减灭性肾切除术或单纯靶向治疗相比,腹腔镜下细胞减灭性肾切除术与显著改善的生存率相关。

Laparoscopic cytoreductive nephrectomy is associated with significantly improved survival compared with open cytoreductive nephrectomy or targeted therapy alone.

作者信息

Zhao Kaidong, Kim Eric H, Vetter Joel M, Hsieh James J, Venkatesh Ramakrishna, Bhayani Sam B, Figenshau R Sherburne

机构信息

Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, P.R. China.

Division of Urologic Surgery, Washington University School of Medicine, St. Louis, MO 63110, USA.

出版信息

Mol Clin Oncol. 2020 Dec;13(6):71. doi: 10.3892/mco.2020.2141. Epub 2020 Sep 21.

Abstract

The aim of the present study was to compare the survival outcomes for patients with metastatic renal cell carcinoma (mRCC) who underwent laparoscopic cytoreductive nephrectomy (CN) vs. open CN vs. targeted therapy (TT) alone at our institution. A retrospective chart review was performed at our institution for patients who underwent CN prior to TT (laparoscopic, n=48; open, n=48) or who were deemed unfit for surgery and received TT alone (n=36), between January 2007 and December 2012. Kaplan-Meier estimated survival and Cox proportional hazards analyses were performed. Laparoscopic CN was associated with significantly longer survival compared with open CN or TT alone (median survival 24 vs. <12 months, respectively; P<0.01). On multivariate analysis, laparoscopic CN was an independent predictor of survival [hazard ratio (HR)=0.48, P<0.01), controlling for preoperative risk factors, while survival was similar between open CN and TT alone (HR=0.85, P=0.54). In our experience, laparoscopic CN appears to be a significant predictor of survival in mRCC. Selection bias of the surgeon for patients with improved survival may account for clinical variables that were otherwise difficult to quantify. For patients who were not candidates for laparoscopic CN, open CN did not confer a survival benefit over TT alone, while it was associated with increased morbidity.

摘要

本研究的目的是比较在我们机构接受腹腔镜减瘤性肾切除术(CN)、开放性CN或单纯靶向治疗(TT)的转移性肾细胞癌(mRCC)患者的生存结局。2007年1月至2012年12月期间,我们机构对在接受TT之前接受CN的患者(腹腔镜手术,n = 48;开放手术,n = 48)或被认为不适合手术并仅接受TT的患者(n = 36)进行了回顾性病历审查。进行了Kaplan-Meier生存估计和Cox比例风险分析。与开放性CN或单纯TT相比,腹腔镜CN与显著更长的生存期相关(中位生存期分别为24个月和<12个月;P<0.01)。多变量分析显示,腹腔镜CN是生存的独立预测因素[风险比(HR)=0.48,P<0.01],校正了术前危险因素,而开放性CN和单纯TT的生存期相似(HR = 0.85,P = 0.54)。根据我们的经验,腹腔镜CN似乎是mRCC患者生存的重要预测因素。外科医生对生存期改善患者的选择偏倚可能解释了其他难以量化的临床变量。对于不适合腹腔镜CN的患者,开放性CN与单纯TT相比并未带来生存获益,同时其与发病率增加相关。

相似文献

5
Oncologic Outcomes of Cytoreductive Nephrectomy in Synchronous Metastatic Renal-Cell Carcinoma: A Single-Center Experience.
Clin Genitourin Cancer. 2018 Dec;16(6):e1189-e1199. doi: 10.1016/j.clgc.2018.07.030. Epub 2018 Aug 11.

引用本文的文献

1
The Evolving Landscape of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma.
Cancers (Basel). 2023 Jul 29;15(15):3855. doi: 10.3390/cancers15153855.

本文引用的文献

1
Cytoreductive nephrectomy in the era of targeted therapies: a review.
BJU Int. 2017 Sep;120(3):320-328. doi: 10.1111/bju.13860. Epub 2017 May 2.
2
Renal cell carcinoma.
Nat Rev Dis Primers. 2017 Mar 9;3:17009. doi: 10.1038/nrdp.2017.9.
4
Systemic Therapy for Metastatic Renal-Cell Carcinoma.
N Engl J Med. 2017 Jan 26;376(4):354-366. doi: 10.1056/NEJMra1601333.
5
Cytoreductive Nephrectomy in the Tyrosine Kinase Inhibitor Era: A Question That May Never Be Answered.
Eur Urol. 2017 Jun;71(6):845-847. doi: 10.1016/j.eururo.2016.10.029. Epub 2016 Nov 1.
7
Minimally invasive cytoreductive nephrectomy: a multi-institutional experience.
World J Urol. 2016 Dec;34(12):1651-1656. doi: 10.1007/s00345-016-1827-1. Epub 2016 Apr 15.
8
Comprehensive Characterization of the Perioperative Morbidity of Cytoreductive Nephrectomy.
Eur Urol. 2016 Jan;69(1):84-91. doi: 10.1016/j.eururo.2015.05.022. Epub 2015 Jun 1.
9
Overall survival advantage with partial nephrectomy: a bias of observational data?
Cancer. 2013 Aug 15;119(16):2981-9. doi: 10.1002/cncr.28141. Epub 2013 May 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验